These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 4078312)

  • 21. [Action of alkaloids from podophyllin on the response of pancreatic beta-cells of the rabbit to tolbutamide].
    Gónzalez Larriba JL; Picaporte MA; Grande C; Gasalla Chacón R; Montero García JM
    Rev Esp Oncol; 1983; 30(4):485-90. PubMed ID: 6400620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantification of teniposide in human serum by high-performance liquid chromatography with electrochemical detection.
    Canal P; Michel C; Bugat R; Soula G; Carton M
    J Chromatogr; 1986 Mar; 375(2):451-6. PubMed ID: 3700571
    [No Abstract]   [Full Text] [Related]  

  • 23. Pediatric cancer chemotherapy: an updated review. I. Cis-Diammine--dichloroplatinum II (cisplatin), VM-26 (teniposide), VP-16 (etoposide), mitomycin C.
    Gutierrez ML; Crooke ST
    Cancer Treat Rev; 1979 Sep; 6(3):153-64. PubMed ID: 394834
    [No Abstract]   [Full Text] [Related]  

  • 24. The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung.
    Roed H; Vindelov LL; Christensen IJ; Spang-Thomsen M; Hansen HH
    Cancer Chemother Pharmacol; 1987; 19(1):16-20. PubMed ID: 3815721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Teniposide (VM26) disposition in children with leukemia.
    Sinkule JA; Stewart CF; Crom WR; Melton ET; Dahl GV; Evans WE
    Cancer Res; 1984 Mar; 44(3):1235-7. PubMed ID: 6581866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 4'-Demethylepipodophyllotoxin-beta-D-glucoside: a new podophyllotoxin derivative with VM-26-like and VP-16-213-like activities.
    Gupta RS; Singh B
    J Natl Cancer Inst; 1984 Jul; 73(1):241-8. PubMed ID: 6588229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycosylated podophyllotoxin congeners: loss of microtubule inhibition and permission of invasion in vitro.
    Mareel MM; Dragonetti CH; De Bruyne GK; Van Cauwenberge RM
    J Natl Cancer Inst; 1982 Dec; 69(6):1367-74. PubMed ID: 6958912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The epipodophyllotoxin derivatives VM-26 and VP-16-213, 1976-1979, a review.
    Nissen NI; Dombernowsky P; Hansen HH; Pedersen AG
    Recent Results Cancer Res; 1980; 74():98-106. PubMed ID: 7003663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunoassay of podophyllotoxin.
    Yoo K; Porter JR
    J Nat Prod; 1993 May; 56(5):715-21. PubMed ID: 8326321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity.
    Kerrigan D; Pommier Y; Kohn KW
    NCI Monogr; 1987; (4):117-21. PubMed ID: 3041238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma.
    Canal P; Bugat R; Michel C; Roche H; Soula G; Combes PF
    Cancer Chemother Pharmacol; 1985; 15(2):149-52. PubMed ID: 4017164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A radioimmunoassay for 5-methyltetrahydrohomofolate.
    Fong KL; Ho DH; Benjamin RS; Yang F; Sickler J; Brown NS; Bodey GP
    J Pharmacol Exp Ther; 1981 Aug; 218(2):344-7. PubMed ID: 6265623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of drug disposition kinetics on cellular transport of the antineoplastic agent VM-26.
    Allen L
    Drug Metab Rev; 1978; 8(1):119-35. PubMed ID: 720213
    [No Abstract]   [Full Text] [Related]  

  • 34. VM 26 and VP 16-213: a comparative analysis.
    Rozencweig M; Von Hoff DD; Henney JE; Muggia FM
    Cancer; 1977 Jul; 40(1):334-42. PubMed ID: 328129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical pharmacology of etoposide and teniposide.
    Clark PI; Slevin ML
    Clin Pharmacokinet; 1987 Apr; 12(4):223-52. PubMed ID: 3297462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative cytotoxic and cytokinetic effects of the epipodophyllotoxins 4'-demethylepipodophyllotoxin-9-(4,6-O-2-ethylidene-beta-D-glucopyranoside) and 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) and their metabolites on human leukemic lymphoblasts.
    Dow LW; Sinkule JA; Look AT; Horvath A; Evans WE
    Cancer Res; 1983 Dec; 43(12 Pt 1):5699-706. PubMed ID: 6580063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Partitioning of teniposide into membranes and the role of lipid composition.
    Wright SE; White JC; Huang L
    Biochim Biophys Acta; 1990 Jan; 1021(2):105-13. PubMed ID: 2302390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetics of cytotoxicity of VM-26 and VP-16-213 on L1210 leukemia and hematopoietic stem cells.
    Vietti TJ; Valeriote FA; Kalish R; Coulter D
    Cancer Treat Rep; 1978 Sep; 62(9):1313-20. PubMed ID: 688275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [In vitro comparison of podophyllotoxin analogues; etoposide, teniposide and NK 611 using human lung cancer cell lines].
    Takigawa N; Ohnoshi T; Ueoka H; Kiura K; Moritaka T; Tabata M; Segawa Y; Shibayama T; Gemba K; Matsumura T
    Gan To Kagaku Ryoho; 1993 Mar; 20(4):473-7. PubMed ID: 8383949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
    Radice PA; Bunn PA; Ihde DC
    Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.